Long-term Follow-up of Bivalent Human Papillomavirus (HPV) Vaccine Study in Women
A Multicenter, Open-label, Long-term Extension Study to Evaluate the Long-term Protective Efficacy and Immunogenic Persistence of the Bivalent Human Papillomavirus Vaccine (Pichia Pastoris) Administered to Healthy Females Aged 18-30 During the 311-HPV-1003 Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Guangxi
-
Lingchuan, Guangxi, China
- Lingchuan Center for Disease Control and Prevention
-
Quanzhou, Guangxi, China
- Quanzhou Center for Disease Control and Prevention
-
Xing'an, Guangxi, China
- Xing'an Center for Disease Control and Prevention
-
-
Hebei
-
Daming, Hebei, China
- Daming Center for Disease Control and Prevention
-
Dingxing, Hebei, China
- Dingxing Center for Disease Control and Prevention
-
Zhengding, Hebei, China
- Zhengding Center for Disease Control and Prevention
-
-
Henan
-
Puyang, Henan, China
- Puyang Center for Disease Control and Prevention
-
Wenxian, Henan, China
- Wenxian Center for Disease Control and Prevention
-
-
Shanxi
-
Xiangfen, Shanxi, China
- Xiangfen County People's Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Have the ability to understand and provide informed consent by signing the informed consent form (non-illiterate).
- Have the ability to comply with protocol requirements, such as attending scheduled visits and responding to follow-up phone calls.
- Prior enrollment in the 311-HPV-1003 study, with at least one dose of the study vaccine administered.
- At least one documented gynecological visit between 6 and 48 months during the previous 311-HPV-1003 study.
- Refrain from vaginal intercourse for 48 hours and avoid behaviors such as vaginal douching or using vaginal medications that could interfere with gynecological examinations or sample collection for 72 hours prior to each gynecological visit.
Exclusion Criteria:
- Participants who received another HPV vaccine during the prior 311-HPV-1003 study or between the end of that study and enrollment in this extension study.
- Participants diagnosed with HPV 16- or 18-related CIN2+ by an independent pathology expert panel during the prior 311-HPV-1003 study, or who were definitively diagnosed with HPV 16- or 18-related CIN2+ through external testing after the prior study ended.
- Participants who, at baseline in the 311-HPV-1003 study, tested positive for both HPV 16 and 18 antibodies, or were positive for both HPV 16 and 18 (by Cobas 4800), or whose cytology was not normal or of low-grade changes.
- Participants who are pregnant at the time of gynecological visits or within three months prior to the visit.
- Participants with any other factors deemed unsuitable for participation in the clinical trial, as determined by the investigator.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
HPV-2 vaccine group
Participants received the bivalent HPV vaccine (0.5 mL in a 3-dose regimen) in the base study (NCT02733068).
No study vaccination will be administered in long-term follow-up study .
|
Recombinant human papillomavirus virus-like particle vaccine (Type 16 and 18 L1 Proteins, Yeast)
|
|
Placebo group
Participants received the placebo (0.5 mL in a 3-dose regimen) in the base study (NCT02733068).
No study vaccination will be administered in long-term follow-up study .
|
Placebo containing the same formulation as the active vaccine (Type 16 and 18 L1 proteins, Yeast) but without the active substance.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Cumulative Protective Efficacy Against HPV-16 and/or HPV-18-Related Cervical Intraepithelial Neoplasia (CIN) Grade 2 or Higher (CIN2+), Adenocarcinoma In Situ (AIS), and Cervical Cancer
Time Frame: Up to 96 months and 120 months after initial vaccination in base study.
|
Up to 96 months and 120 months after initial vaccination in base study.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Cumulative protective efficacy against cytological HPV-16 and/or HPV-18 infection
Time Frame: Up to 96 months and 120 months after initial vaccination in base study.
|
Up to 96 months and 120 months after initial vaccination in base study.
|
|
Cumulative protective efficacy against HPV-16 and/or HPV-18-related CIN1+
Time Frame: Up to 96 months and 120 months after initial vaccination in base study.
|
Up to 96 months and 120 months after initial vaccination in base study.
|
|
HPV 16/18 neutralizing antibody GMT and seropositivity rates
Time Frame: At 96 months and 120 months after initial vaccination in base study.
|
At 96 months and 120 months after initial vaccination in base study.
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Pathologic Processes
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Disease Attributes
- Infections
- Virus Diseases
- Uterine Diseases
- Genital Diseases, Female
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- DNA Virus Infections
- Genital Neoplasms, Female
- Precancerous Conditions
- Uterine Cervical Diseases
- Tumor Virus Infections
- Vulvar Diseases
- Vaginal Diseases
- Papillomavirus Infections
- Vulvar Neoplasms
- Uterine Cervical Dysplasia
- Vaginal Neoplasms
Other Study ID Numbers
Other Study ID Numbers
- 311-HPV-1003-EXTEND (Other Identifier: Shanghai Zerun Biotech)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.